

## INOVIQ SIGNS KEY MANUFACTURING AGREEMENT TO ADVANCE ITS SUBB2M-BASED TESTS

- INOVIQ has executed a Master Manufacturing Agreement with MP Biomedicals for production of the SubB2M protein for the Company's SubB2M-based tests
- INOVIQ's SubB2M technology detects the pan-cancer biomarker Neu5Gc found at elevated levels in multiple human cancers
- SubB2M-based tests are in-development for multiple uses including monitoring breast and ovarian cancers, and for a general health panel
- MP Biomedicals is a global supplier of life science and diagnostic products
- Agreement with MP Biomedicals enables production of cGMP protein for commercial SubB2M tests and represents a key milestone for INOVIQ

**Melbourne, Australia, 2 May 2022:** INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that it has executed a Master Manufacturing Agreement with MP Biomedicals, a global supplier of life science and diagnostic products, for the contract manufacture of INOVIQ's proprietary SubB2M protein.

### SubB2M technology and pipeline

The SubB2M protein is a key reagent used in INOVIQ's SubB2M-based tests for the monitoring and detection of cancer. SubB2M specifically detects the pan-cancer biomarker Neu5Gc that is found in multiple human cancers, including breast, ovarian, prostate and others. INOVIQ holds the exclusive worldwide licence from the University of Adelaide to the SubB2M technology for use in diagnostic applications.

INOVIQ's SubB2M diagnostics pipeline includes SubB2M-based immunoassays for monitoring breast and ovarian cancers, and a SubB2M-based surface plasmon resonance (SPR) test for the detection of Neu5Gc levels in a general health panel.

The Company recently signed a Master Services Agreement with US-based contract diagnostics organisation ResearchDx to further the development and validation of its SubB2M-based tests in the USA (ASX: 5 April 2022). This manufacturing agreement enables production of high-quality cGMP grade SubB2M protein required by ResearchDx to complete commercial development of the SubB2M tests.

### Master Manufacturing Agreement with MP Biomedicals

The Master Manufacturing Agreement with MP Biomedicals Asia Pacific Pte Ltd is for the provision of contract manufacturing services to produce the SubB2M protein to cGMP standard. Manufacturing will take place in MP Biomedicals' Singapore facility.

The agreement follows the successful technology transfer of the SubB2M manufacturing and quality control processes from the University of Adelaide to MP Biomedicals for the routine production and testing of the protein (required prior to release) for commercial applications.

The manufacture of the SubB2M protein at MP Biomedicals' cGMP and ISO 13485 certified Singapore facility will be an important milestone for INOVIQ as it will ensure:

- Manufacture of the SubB2M protein in a cGMP (current Good Manufacturing Practice) environment, under an ISO 13485 accredited quality assurance program
- Streamlined production process for cost effective manufacture and release of SubB2M protein

- Material that may be used in a range of applications, including for research, clinical development, and in vitro diagnostic commercial applications
- A scalable production process enabling continuity of supply of the SubB2M protein for INOVIQ's in-development SubB2M-based diagnostic tests.

MP Biomedicals, Director - Sales and Marketing (APAC), Beng Kuan Choo said, *"We are very excited to be partnering with INOVIQ to supply high-quality SubB2M protein for the Company's innovative SubB2M-based diagnostic tests. We are fully committed to deliver consistent supply of high-quality SubB2M as we believe that the SubB2M-based tests could play an important role in improving patient outcomes for monitoring breast, ovarian and other cancers."*

INOVIQ CEO Dr Learne Hinch said, *"Securing commercial supply of the SubB2M protein is a key milestone for INOVIQ. MP Biomedicals is a highly respected global supplier of life science and diagnostic products and we are therefore delighted to partner with them to ensure the commercial supply of SubB2M protein, which are critical components of our SubB2M-based tests for breast and ovarian cancer."*

INOVIQ would like to acknowledge funding support for its SubB2M program from the Biomedical Translation Bridge (BTB) program, which is delivered by MTPConnect and is part of the Australian Government's Medical Research Future Fund.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

## COMPANY CONTACTS

**Dr Learne Hinch**  
Chief Executive Officer  
E [lhinch@inoviq.com](mailto:lhinch@inoviq.com)  
M +61 400 414 416

**Dr Geoff Cumming**  
Non-executive Chairman  
E [geoff.cumming@inoviq.com](mailto:geoff.cumming@inoviq.com)  
M +61 417 203 021

**Jane Lowe**  
IR Department  
E [jane.lowe@irdepartment.com.au](mailto:jane.lowe@irdepartment.com.au)  
M +61 411 117 774

## ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising innovative diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see [www.inoviq.com](http://www.inoviq.com).

## ABOUT MP Biomedicals

MP Biomedicals, is a global corporation developing, manufacturing, and distributing products for the life science, in vitro diagnostics (IVD) and biotech industries. Through our global operational network, we provide the research, healthcare, and industrial communities with innovative, quality tools to aid in research for groundbreaking discoveries and disease control. For more information about MP Biomedicals, please visit [www.mpbio.com/about-us](http://www.mpbio.com/about-us).

## FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.